Last reviewed · How we verify
Mebendazole polymorph C
Mebendazole polymorph C inhibits microtubule assembly in parasitic worms by binding to β-tubulin, disrupting their motility and nutrient uptake.
Mebendazole polymorph C inhibits microtubule assembly in parasitic worms by binding to β-tubulin, disrupting their motility and nutrient uptake. Used for Helminthic infections (nematodes and cestodes), Soil-transmitted helminth infections.
At a glance
| Generic name | Mebendazole polymorph C |
|---|---|
| Also known as | Lot FG10H01 |
| Sponsor | University of Kelaniya |
| Drug class | Benzimidazole anthelmintic |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Mebendazole is a benzimidazole anthelmintic that binds to β-tubulin and prevents microtubule polymerization in nematodes and some cestodes. This disruption of the parasite's cytoskeletal structure leads to immobilization, reduced glucose uptake, and eventual death. Polymorph C represents a specific crystalline form of mebendazole, potentially optimized for improved bioavailability or efficacy.
Approved indications
- Helminthic infections (nematodes and cestodes)
- Soil-transmitted helminth infections
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mebendazole polymorph C CI brief — competitive landscape report
- Mebendazole polymorph C updates RSS · CI watch RSS
- University of Kelaniya portfolio CI